Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.13 Analyst target: $10.50 Upside: 829.20%
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.